In patients with pancreatic and thyroid cancers, TRIM21 overexpression has been associated with poor prognosis, whereas in patients with diffuse large B-cell lymphoma and ovarian, gastric, and breast cancers, low TRIM21 levels have been linked to negative clinical outcomes.24 Here, TRIM21 is linked to breast carcinoma.